<?xml version="1.0" encoding="UTF-8"?>
<p id="Par25">Since the first reports of the disease by Guillain, Barré and Strohl in 1916
 <sup>
  <xref ref-type="bibr" rid="CR78">78</xref>
 </sup> our knowledge of Guillain-Barré syndrome (GBS) has exponentially increased over the last century.
 <sup>
  <xref ref-type="bibr" rid="CR79">79</xref>
 </sup> In particular, IgG AGAs are found in more than half of GBS patients and are strongly indicative of the disease, while the role of IgM is still not clear.
 <sup>
  <xref ref-type="bibr" rid="CR80">80</xref>
 </sup> GBS a is the most common cause of a flaccid pararalysis worldwide. It is considered to be a postinfectious, inflammatory, peripheral neuropathy.
 <sup>
  <xref ref-type="bibr" rid="CR81">81</xref>
 </sup> Clinically, it is characterized by weakness and areflexia or hyporeflexia in all four limbs.
 <sup>
  <xref ref-type="bibr" rid="CR82">82</xref>,
  <xref ref-type="bibr" rid="CR83">83</xref>
 </sup> GBS has a plethora of variants but the most relevant ones are an acute inflammatory demyelinating polyneuropathy (AIDP), the axonal forms (AMAN and AMSAN), Miller–Fisher syndrome (MFS) and Bickerstaff brainstem encephalitis (BEE).
</p>
